Gut-derived uremic toxin trimethylamine-N-oxide in cardiovascular disease under end-stage renal disease: an injury mechanism and therapeutic target.
10.7507/1001-5515.202110017
- Author:
Yuan REN
1
;
Zuoyuan WANG
1
;
Jun XUE
1
Author Information
1. Department of Nephrology, Huashan Hospital, Fudan University, Shanghai 200040, P. R. China.
- Publication Type:Review
- Keywords:
Atherosclerosis;
Cardiovascular disease;
End-stage renal disease;
Trimethylamine-N-oxide
- MeSH:
Cardiovascular Diseases;
Humans;
Kidney Failure, Chronic;
Methylamines;
Oxides;
Uremic Toxins
- From:
Journal of Biomedical Engineering
2022;39(4):848-852
- CountryChina
- Language:Chinese
-
Abstract:
The main cause of death in patients with end-stage renal disease (ESRD) is cardiovascular disease, and trimethylamine-N-oxide (TMAO) has been found to be one of the specific risk factors in the pathogenic process in recent years. TMAO is derived from intestinal bacterial metabolism of dietary choline, carnitine and other substances and subsequently catalyzed by flavin monooxygenase enzymes in the liver. The changes of intestinal bacteria in ESRD patients have contributed to the accumulation of gut-derived uremic toxins such as TMAO, indoxyl sulfate and indole-3-acetic acid. While elevated TMAO concentration accelerates atherosclerosis through mechanisms such as inflammation, increased scavenger receptor expression, and inhibition of reverse cholesterol transport. In this review, this research introduces the biological function, metabolic processes of TMAO and mechanisms by which TMAO promotes the progression of cardiovascular disease in ESRD patients and summarizes current interventions that may be used to reverse gut microbiota disturbances, such as activated carbon, fecal microbial transplantation, dietary improvement, probiotic and probiotic introduction. It also focuses on exploring intervention targets to reduce the gut-derived uremic toxin TMAO in order to explore the possibility of more cardiovascular disease treatments for ESRD patients.
